Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P422. The Biologics Register for inflammatory bowel disease in the UK: Setting the clinical dataset and the IT infrastructure
P422

'IBDPassport': Evaluating the quality of an internet-based travel resource for Inflammatory Bowel Disease

Authors:

K. Greveson*, M. Hamilton, C.D. Murray

Royal Free Hospital, Department of Gastroenterology, London, United Kingdom

P423.

Long term outcome for sequential rescue treatments in steroid refractory ulcerative colitis – a real life experience

Authors:

M. Protic1, F. Seibold2, A. Shoepfer3, Z. Radojicic4, P. Juillerat5, D. Bojic1, J. Mwinyi6, C. Mottet7, N. Jojic1, C. Beglinger8, S. Vavricka9, G. Rogler6, P. Frei10, 1University Hospital Zvezdara, Department of Gastroenterology, Belgrade, Serbia, 2Tiefenau Spital, Department of Gastroenterology, Bern, Switzerland, 3Centre Hospitalier Universitaire Vaudois, Gastroenterology, Lausanne, Switzerland, 4Faculty of Organizational Sciences, Department of Statistics, Belgrade, Serbia, 5University Hospital Bern, Gastroenterology and Hepatology, Bern, Switzerland, 6University Hospital Zurich, Gastroenterology & Hepatology, Zurich, Switzerland, 7Hospital Neuchâtel, Department of Gastroenterology, Neuchâtel, Switzerland, 8University Hospital Basel, Division of Gastroenterology & Hepatology, Basel, Switzerland, 9Stadtspital Triemli, Department of Gastroenterology, Zürich, Switzerland, 10See Spital, Department of Gastroenterology, Zürich, Switzerland

P423. A new measure to assess quality of care from the patient perspective during the transitional phase
P423. Our experience with single incision laparoscopic surgery in inflammatory bowel disease patients
Authors:

M. Marti-Gallostra1, E. Espin1, F. Vallribera1, J.L. Sanchez-García1, L.M. Jiménez-Gómez1, V. Robles2, N. Boruel2, M. Armengol-Carrasco3, 1Hospital Universitary de la Vall d'Hebron, Colorectal surgery, Barcelona, Spain, 2Hospital Universitary de la Vall d'Hebron, Gastroenterology, Barcelona, Spain, 3Hospital Universitary de la Vall d'Hebron, General and Digestive Surgery, Barcelona, Spain

P423

Evaluation and long-term benefit of mucosal healing in Crohn's disease patients treated with infliximab

Authors:

L. Libier*1, M. Collins2, D. Koriche3, M. Nachury1, C. Gower-Rousseau4, P. Zerbib3, A. Cortot5, J.-F. Colombel6, P. Desreumaux1, G. Pineton de Chambrun7

1CHU de Lille, Department of Gastroenterology, Lille, France, 2APHP Paris Sud University , Gastroenterology, Le Kremlin Bicêtre, France, 3Lille University Hospital, Colorectal Surgery Department , Lille, France, 4Lille University Hospital, North of France University, Epidemiology, Lille, France, 5Lille University Hospital, North of France University, Gastroenterology, Lille, France, 6Mount Sinai Hospital, Gastroenterology, New-York, United States, 7Montpellier 1 University, Gastroenterology and Hepatology, Montpellier, France

P424.

Long term efficacy of granulocyte-monocyte-apheresis in ulcerative colitis. The Italian Registry of Therapeutic Apheresis

Authors:

R. Sacco1, V. D'Ovidio2, S. Passalacqua3, P. Ferraro3, M.B. Principi4, M. Astegiano5, R. Testa6, R. D'Incà7, A. Armuzzi8, D. Valpiani9, M.L. Guidi10, F. Costa1, A.L. Aratari11, C. Ricci12, G. Riegler13, E. Colombo14, G. Repaci15, P. Lecis16, M. Silla17, M. Vecchi18, G. Bresci1, 1Pisa University Hospital, Gastroenterology, Pisa, Italy, 2Policlinico Umberto I, Gastroenterology, Rome, Italy, 3Catholic University, Nephrology, Rome, Italy, 4University of Bari, Gastroenterology, Bari, Italy, 5ASO Molinette, Gastroenterology, Turin, Italy, 6S.Corona Hospital, Gastroenterology, Pietra Ligure, Italy, 7University of Padova, Gastroenterology, Padova, Italy, 8Columbus University, Internal Medicine, Roma, Italy, 9Ospedale Morgagni, Gastroenterology, Forli', Italy, 10Catholic University, Gastroenterology, Rome, Italy, 11San Filippo Neri Hospital, Gastroenterology, Rome, Italy, 12Spedali Civili, Gastroenterology, Brescia, Italy, 13SUN University, Gastroenterology, Napoli, Italy, 14AUC Careggi, Gastroenterology, Firenze, Italy, 15Azienda Ospedaliera Legnano, Gastroenterology, Magenta, Italy, 16Ospedale S.Martino, Gastroenterology, Belluno, Italy, 17Ospedale di Vasto, Gastroenterology, Vasto, Italy, 18San Donato Milanese Hospital, Gastroenterology, San Donato Milanese, Italy

P424. A cost analysis of alicaforsen compared with infliximab or surgery for chronic, unremitting pouchitis in the UK
P424. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era
Authors:

L. Thin1, K. Murray2, I. Lawrance3, 1Centre for Inflammatory Bowel diseases, Fremantle Hospital, Fremantle, Australia, 2Centre for Applied Statistics, University of Western Australia, Crawly, Australia, 3Centre for Inflammatory Bowel diseases, Fremantle Hospital, University of Western Australia, Fremantle, Australia

P424

Th1 and Th17 response in relation with steroid response in Crohn's disease

Authors:

A. Carrasco*, F. Fernández-Bañares, Y. Zabana, M. Aceituno, M. Rosinach, X. Andújar, C. Loras, R. Temiño

Hospital Universitari Mútua Terrassa, UB, Gastroenterology, Terrassa, Spain

P425.

Long term effects of anti-TNF-therapy on bone mass in IBD, a retrospective cohort study

Authors:

R.L. Roscam Abbing1, N.M. Appelman-Dijkstra2, R.A. Veenendaal1, N.A. Hamdy2, A.E. van der Meulen-de Jong1, 1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Center, Center for bone quality, Leiden, Netherlands

P425. Does contact with industrial products increase the risk for developing inflammatory bowel disease? A case–control study
P425. One-year outcomes of ustekinumab therapy in a multi-drug refractory Crohn's disease cohort
Authors:

D. Ginard1, S. Khorrami1, I. Marín2, M. Chaparro3, M. Aguas4, J. Martínez-González5, J.L. Cabriada6, V. García-Sánchez7, A. Villoria8, J. Gelabert9, F. Casellas10, A. Sansó11, J. Riera12, D. Hervías13, S. García14, E. García-Planella15, J.P. Gisbert3, 1Hospital Son Espases, Gastroenterology, Palma de Mallorca, Spain, 2Hospital Gregorio Marañón, Gastroenterology, Spain, 3Hospital de La Princesa, IP and CIBEREHD, Gastroenterology, Spain, 4Hospital La Fe, Gastroenterology, Valencia, Spain, 5Hospital Ramón y Cajal, Gastroenterology, Spain, 6Hospital Galdakao, Gastroenterology, Spain, 7Hospital Reina Sofía, Gastroenterology, Spain, 8Hospital Parc Taulí, Gastroenterology, Spain, 9Hospital Mateo Orfila, Gastroenterology, Mahón, Spain, 10Hospital Vall D'Hebrón, Gastroenterology, Spain, 11Hospital de Manacor, Gastroenterology, Spain, 12Hospital Son Llàtzer, Gastroenterology, Spain, 13Hospital Virgen de Altagracia, Gastroenterology, Spain, 14Hospital Miguel Servet, Gastroenterology, Spain, 15Hospital de la Santa Creu y de San Pau, Gastroenterology, Spain

P425

Endothelial function and cardiovascular risk in Inflammatory Bowel Disease in remission phase

Authors:

L. Montenegro*, G. Losurdo, A. Zito, M.M. Ciccone, E. Ierardi, A. Di Leo, M. PRINCIPI

University of Bari, DETO, Bari, Italy

P426.

Long-term safety of adalimumab in paediatric patients with Crohn's disease

Authors:

J. Rosh1, F. Ruemmele2, M. Dubinsky3, J. Escher4, J. Kierkus5, J. Hyams6, A. Lazar7, S. Eichner8, Y. Li8, R.B. Thakkar8, 1Goryeb Children's Hospital/Atlantic Health, Pediatric Gastroenterology, Morristown, United States, 2Universite Sorbonne Paris-Cite, Hospital Necker-Enfants Malades, APHP, Paris, France, 3Cedars-Sinai Medical Center, Pediatric Inflammatory Bowel Disease Program, Los Angeles, United States, 4Erasmus MC-Sophia Children's Hospital, Pediatric Gastroenterology, Rotterdam, Netherlands, 5The Children's Memorial Health Institute, Gastroenterology, Hepatology and Feeding Disorders, Warsaw, Poland, 6Connecticut Children's Medical Center, Division of Digestive Diseases, Hartford, United States, 7AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany, 8AbbVie Inc, GPRD, North Chicago, United States

P426. A nation-wide registry of pediatric IBD: Epidemiology, activity indices, laboratory data, therapeutic managements, and one year follow-up
P426. Novel apheresis device removes platelets and platelet aggregates: a postmarketing surveillance study
Authors:

G. Waitz1, H. Prophet2, W. Ramlow2, 1BioArtProducts GmbH, Rostock, Germany, 2Apheresis Center Rostock, Rostock, Germany

P426

Disease phenotype, activity, and clinical course based on the C-reactive protein level at diagnosis in Crohn's Disease: results from the CONNECT study

Authors:

J.H. Kwon*1, J.P. Im1, J.S. Kim1, J.H. Cheon2, W.H. Kim2, Y.S. Kim3, B.D. Ye4, K.M. Lee5, Y.H. Kim6, D.S. Han7

1Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea, Republic of, 2Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea, Republic of, 3Inje University College of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 4Asan Medical Center,University of Ulsan College of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 5Catholic University College of Medicine, Saint Vincent Hospital, Department of Internal Medicine, Suwon, Korea, Republic of, 6Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 7Hanyang University Guri Hospital, Department of Internal Medicine, Guri, Korea, Republic of

P427.

Long-term outcomes of ulcerative colitis patients on thiopurine maintenance treatment

Authors:

S. Yamada1, T. Yoshino1, N. Minami1, T. Toyonaga2, Y. Honzawa1, M. Matsuura1, H. Nakase1, 1Graduate school of Medicine, Kyoto University, Department of gastroenterology and hepatology, Kyoto, Japan, 2Kansai Medical University, The Third Department of Internal Medicine, Takatsuki, Japan

P427. Information seeking activity and adherence to therapy: Findings from the Swiss Inflammatory Bowel Disease Cohort Study